upiter Wellness, Inc. (NASDAQ:JUPW), a wellness company focused on hair loss, eczema, burns, and sexual wellness announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for patent application No. 16/747,685, titled “Minoxidil Adjuvant Therapies.” Jupiter Wellness acquired this case through its recent acquisition of Applied Biology assets.
The patent relates to the composition and methods for inducing (up-regulating) the expression of sulfotransferases in the hair follicles on the scalp. Induction of the sulfotransferase enzyme in hair follicles increases the sulfonation capacity of minoxidil; thus, increasing the response level to oral and topical minoxidil in the treatment of alopecia.
Dr. Glynn Wilson, Chief Scientific Officer said, “This new patent bolsters our growing position in the hair loss market and further protects our continued investment in the market. Patents covering compositions and methods provide some of the strongest protections a patent can provide. Through the acquisition of Applied Biology assets and the continued work of our team, we are even more strongly positioned to expand our reach in the global hair loss treatment market.”
Jupiter Wellness has licensed the minoxidil adjuvant therapies covered by this patent to Taisho Pharmaceutical Co. Ltd, the largest marketer of minoxidil in Japan.
About Jupiter Wellness
Jupiter Wellness is a
diversified company supporting health and wellness through the research
and development of over-the-counter (OTC) products and intellectual
property. The Company's product pipeline addresses a range of
conditions, including hair loss, eczema, burns, and sexual wellness.
Revenue is generated through the sales of OTC and consumer products,
contract research agreements, and licensing royalties.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://jupiterwellness.com/email-alerts/ and by following Jupiter Wellness on Twitter and LinkedIn.
No comments:
Post a Comment